Heart Failure With Preserved Ejection Fraction Clinical Trials

32 studies are recruiting for heart failure with preserved ejection fraction in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Boston, Massachusetts 6 Dallas, Texas 6 New York, New York 6 Philadelphia, Pennsylvania 6 Rochester, Minnesota 6 Indianapolis, Indiana 5 Ann Arbor, Michigan 4 Birmingham, Alabama 4 Pittsburgh, Pennsylvania 4 San Antonio, Texas 4 Winston-Salem, North Carolina 4 Atlanta, Georgia 3 Baltimore, Maryland 3 Chicago, Illinois 3 Cincinnati, Ohio 3 Detroit, Michigan 3 Durham, North Carolina 3 Houston, Texas 3 Kansas City, Missouri 3 Tucson, Arizona 3

Studies now recruiting

  1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    University of Alabama Saint Vincent's Birmingham, Birmingham, Alabama
    Locations
    657 in total
    Run by
    Amgen

    See if you can join NCT07037459 on ClinicalTrials.gov

  2. A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

    This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

    Stage
    Phase 2
    Ages
    30 to 84
    Site
    Local Institution - 149, Vista, California
    Locations
    25 in total
    Run by
    Edgewise Therapeutics, Inc.

    See if you can join NCT07795814 on ClinicalTrials.gov

  3. Incretin Therapies in Obesity-related HFpEF

    The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this …

    Stage
    Phase 4
    Ages
    40 and older
    Site
    Columbia University Irving Medical Center (CUIMC) / NewYork Presbyterian Hospital (NYP), New York, New York
    Run by
    Columbia University

    See if you can join NCT07554638 on ClinicalTrials.gov

  4. A Preliminary Study for INFORMED

    Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adu…

    Stage
    Phase 4
    Ages
    65 and older
    Site
    Weill Cornell Medicine, New York, New York
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05585125 on ClinicalTrials.gov

  5. Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction

    The purpose of this study is to internally validate low-field Ex-CMR as a noninvasive tool for diagnosing, phenotyping, and risk stratifying HFpEF in patients with exertional dyspnea.

    Stage
    Not phased
    Ages
    18 to 80
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Run by
    Mayo Clinic

    See if you can join NCT07401771 on ClinicalTrials.gov

  6. A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

    The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left hear…

    Stage
    Not phased
    Ages
    18 to 85
    Site
    Banner - University Medical Center Tucson, Tucson, Arizona
    Locations
    6 in total
    Run by
    Pulnovo Medical, Inc.

    See if you can join NCT07214376 on ClinicalTrials.gov

  7. HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

    Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigational Site-101, Greenville, South Carolina
    Run by
    35Pharma Inc

    See if you can join NCT07123779 on ClinicalTrials.gov

  8. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Grandview Medical Group Research, LLC, Birmingham, Alabama
    Locations
    105 in total
    Run by
    Impulse Dynamics

    See if you can join NCT05064709 on ClinicalTrials.gov

  9. Ketogenic Diet vs Mixed Diet in Patients With Heart Failure

    This study is being done to evaluate the effects of a low carbohydrate ketogenic diet (KD) versus a low-fat diet (MD) on exercise tolerance in participants with heart failure with normal pumping function and diabetes or pre-diabetes, or metabolic syndrome, or obesity.

    Stage
    Not phased
    Ages
    18 to 80
    Site
    The Ross Heart Hospital, Columbus, Ohio
    Run by
    Ohio State University

    See if you can join NCT06081543 on ClinicalTrials.gov

  10. EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

    The goal of this clinical trial is to learn if therapy with activin ligand-trap biological therapy (an investigational drug) combined with exercise training can improve exercise capacity and cognitive function in heart failure with preserved ejection fraction (HFpEF). The main questions it aims to …

    Stage
    Phase 2
    Ages
    40 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Run by
    Massachusetts General Hospital

    See if you can join NCT07202000 on ClinicalTrials.gov

  11. A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

    The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Run by
    Mayo Clinic

    See if you can join NCT07083011 on ClinicalTrials.gov

  12. Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction

    The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failur…

    Stage
    Not phased
    Ages
    60 and older
    Site
    Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
    Run by
    Wake Forest University Health Sciences

    See if you can join NCT05525663 on ClinicalTrials.gov

  13. Matching Perfusion and Metabolic Activity in HFpEF

    This study will test whether pharmacologic agents that increase perfusion [Potassium Nitrate (KNO3)], with and without additional supplements that may improve mitochondrial function [Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)], improve submaximal exercise endurance and skeletal musc…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    University of Pennsylvania

    See if you can join NCT04913805 on ClinicalTrials.gov

  14. BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching

    Heart failure with preserved ejection fraction (HFpEF) represents a major public health burden that is both growing rapidly and has few effective therapies. Supervised exercise training (SET) is one of the few effective therapies for older patients with HFpEF, but is currently constrained by cost, …

    Stage
    Not phased
    Ages
    55 and older
    Site
    Wake Forest University Health Sciences, Winston-Salem, North Carolina
    Run by
    Wake Forest University Health Sciences

    See if you can join NCT07413198 on ClinicalTrials.gov

  15. Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

    The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contrib…

    Stage
    Not phased
    Ages
    55 to 90
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT05723679 on ClinicalTrials.gov

  16. Novel Approaches for Improving Vascular Function in Veterans With HFpEF

    This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
    Run by
    VA Office of Research and Development

    See if you can join NCT06312748 on ClinicalTrials.gov

  17. SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

    This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism [Empagliflozin (Empa)], with and without additional supplements that increase perfusion and fatty acid oxidation [Potassium Nitrate (KNO3)], improve submaximal exercise endurance and…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Pennsylvania Health System, Philadelphia, Pennsylvania
    Run by
    University of Pennsylvania

    See if you can join NCT05138575 on ClinicalTrials.gov

  18. HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

    HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes …

    Stage
    Not phased
    Ages
    30 and older
    Site
    University of California Davis, Sacramento, California
    Locations
    6 in total
    Run by
    Northwestern University

    See if you can join NCT05873634 on ClinicalTrials.gov

  19. Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

    The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new trea…

    Stage
    Not phased
    Ages
    30 and older
    Site
    Northwestern University, Chicago, Illinois
    Locations
    6 in total
    Run by
    Northwestern University

    See if you can join NCT06517186 on ClinicalTrials.gov

  20. SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

    The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.

    Stage
    EARLY_Phase 1
    Ages
    18 to 80
    Site
    University of Texas Health Science Center at San Antonio, San Antonio, Texas
    Run by
    The University of Texas Health Science Center at San Antonio

    See if you can join NCT05057806 on ClinicalTrials.gov

  21. Purinergic Signaling and the Postmenopausal Heart

    There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic …

    Stage
    Not phased
    Ages
    30 to 88
    Site
    Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Run by
    Beth Israel Deaconess Medical Center

    See if you can join NCT06015776 on ClinicalTrials.gov

  22. Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

    The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Yale New Haven Health System, New Haven, Connecticut
    Run by
    Yale University

    See if you can join NCT04237701 on ClinicalTrials.gov

  23. A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

    To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mayo Clinic, Rochester, Minnesota
    Run by
    Mayo Clinic

    See if you can join NCT07093528 on ClinicalTrials.gov

  24. Transitions of Care Clinic (TOCC)

    The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multip…

    Stage
    Not phased
    Ages
    18 to 90
    Site
    Ocean University Medical Center, Brick, New Jersey
    Run by
    Hackensack Meridian Health

    See if you can join NCT06937827 on ClinicalTrials.gov

  25. Leg Heat Therapy in Heart Failure With Preserved Ejection Fraction

    The objective of this pilot study is to establish evidence to support the validity of HT in improving skeletal muscle function and physical capacity of patients with HFpEF. Our central hypothesis is that HT treatment will lead to improvements in skeletal muscle and microvascular function compared t…

    Stage
    Not phased
    Ages
    18 and older
    Site
    IU Health Methodist, Indianapolis, Indiana
    Locations
    2 in total
    Run by
    Indiana University

    See if you can join NCT06388226 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.